Evidence map›Paper›PMID 34350454›Full record

ArticleJapanese journal of clinical oncology2021

Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma.

Yoshihiko Tomita, Go Kimura, Satoshi Fukasawa, Kazuyuki Numakura, Yutaka Sugiyama, Kazutoshi Yamana, Sei Naito, Hirokazu Kaneko, Yohei Tajima, Mototsugu Oya

Erratum issuedOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Japanese journal of clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Observational
  5. Review
  6. Observational
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 1 country.

Yoshihiko TomitaDepartment of Urology, Molecular Oncology, Graduate School of Medicine and Dental Sciences, Niigata University, Niigata, Japan.
Go KimuraDepartment of Urology, Nippon Medical School Hospital, Tokyo, Japan.
Satoshi FukasawaProstate Center and Division of Urology, Chiba Cancer Center, Chiba, Japan.
Kazuyuki NumakuraDepartment of Urology, Akita University Graduate School of Medicine, Akita, Japan.
Yutaka SugiyamaDepartment of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Kazutoshi YamanaDepartment of Urology, Molecular Oncology, Graduate School of Medicine and Dental Sciences, Niigata University, Niigata, Japan.
Sei NaitoDepartment of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan.
Hirokazu KanekoBristol-Myers Squibb, Tokyo, Japan.
Yohei TajimaOno Pharmaceutical Co., Ltd., Osaka, Japan.
Mototsugu OyaDepartment of Urology, Keio University School of Medicine, Tokyo, Japan.
Niigata University · JPAkita University · JPBristol-Myers Squibb (Japan) · JPChiba Cancer Center · JPKeio University · JPKumamoto University · JPNippon Medical School Hospital · JPOno Pharmaceutical (Japan) · JPYamagata University · JP

Funding

Ono Pharmaceutical Co., Ltd.
6 · The paper itself

Abstract

backgroundWe performed subgroup analyses of the AFTER I-O study to clarify the association of time-to-treatment failure (TTF) and discontinuation reason of prior immune-oncology (I-O) therapy, and molecular targeted therapy (TT) regimen with the outcomes of TT after I-O.

methodsThe data of Japanese metastatic renal cell carcinoma patients treated with TT after nivolumab (NIVO) (CheckMate 025) or NIVO + ipilimumab (IPI) (CheckMate 214) were retrospectively analyzed. The objective response rates (ORRs), progression-free survival (PFS) and overall survival (OS) of TT after I-O were analyzed by subgroups: TTF (<6 or ≥6 months) and discontinuation reason of prior I-O (progression or adverse events), and TT regimen (sunitinib or axitinib). We also analyzed PFS2 of prior I-O and OS from first-line therapy.

resultsThe ORR and median PFS of TT after NIVO and NIVO+IPI among the subgroups was 17-36% and 20-44%, and 7.1-11.6 months and 16.3-not reached (NR), respectively. The median OS of TT after NIVO was longer in patients with longer TTF of NIVO and treated with axitinib. Conversely, median OS of TT after NIVO+IPI was similar among subgroups. The median PFS2 of NIVO and NIVO+IPI was 36.7 and 32.0 months, respectively. The median OS from first-line therapy was 70.5 months for patients treated with NIVO and NR with NIVO+IPI. The safety profile of each TT after each I-O was similar to previous reports.

conclusionsThe efficacy of TT after NIVO or NIVO+IPI was favorable regardless of the TTF and discontinuation reason of prior I-O, and TT regimen.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansIpilimumabJapanMolecular Targeted TherapyRetrospective StudiesIpilimumabipilimumabmolecular targeted therapynivolumabrenal cell carcinoma

Identifiers

PMID34350454
PMCPMC8558912
OpenAlexW3192733112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.